Anzeige
Mehr »
Samstag, 26.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EVX4 | ISIN: US6409791000 | Ticker-Symbol:
NASDAQ
25.07.25 | 21:59
2,340 US-Dollar
+2,18 % +0,050
1-Jahres-Chart
NEUMORA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NEUMORA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NEUMORA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNeumora Therapeutics, Inc.: Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 20256
16.07.Mizuho raises Neumora Therapeutics stock price target on new drug candidate4
16.07.Mizuho hebt Kursziel für Neumora Therapeutics nach Vorstellung neuen Wirkstoffkandidaten an14
10.07.H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock4
09.07.Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861237NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits...
► Artikel lesen
NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln
30.05.Neumora Therapeutics, Inc. - 8-K, Current Report7
16.05.Neumora Therapeutics, Inc. - 8-K, Current Report3
12.05.Neumora Therapeutics GAAP EPS of -$0.42 misses by $0.038
12.05.Neumora Therapeutics, Inc. - 10-Q, Quarterly Report2
12.05.Neumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update287On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major...
► Artikel lesen
22.04.Former Neumora CEO to lead Galapagos spinout6
02.04.BofA cuts Neumora stock rating to underperform, target to $16
10.03.Neumora stock rating cut to Market Perform at William Blair5
10.03.Neumora stock holds Buy rating and $18 target from H.C. Wainwright3
07.03.Neumora cut to Hold at Stifel after J&J's VENTURA exit6
07.03.Guggenheim cuts Neumora Therapeutics stock rating to neutral5
07.03.Stifel cuts Neumora Therapeutics stock rating to hold6
04.03.Neumora bids farewell to R&D head; Biohaven's 'one step forward, one step back' data10
03.03.Neumora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Guggenheim maintains buy on Neumora shares, target at $74
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2